Literature DB >> 24950307

Deletion of Ptp4a3 reduces clonogenicity and tumor-initiation ability of colitis-associated cancer cells in mice.

Julie M Cramer1,2, Mark W Zimmerman3, Tim Thompson4, Gregg E Homanics3,5, John S Lazo3, Eric Lagasse1,2.   

Abstract

The PTP4A3 gene is highly expressed in human colon cancer and often associates with enhanced metastatic potential. Genetic disruption of the mouse Ptp4a3 gene reduces the frequency of colon tumor formation in mice treated in a colitis-associated cancer model. In the current study, we have examined the role of Ptp4a3 in the tumor-initiating cell population of mouse colon tumors using an in vitro culture system. Tumors generated in vivo following AOM/DSS treatment were isolated, dissociated, and expanded on a feeder layer resulting in a CD133(+) cell population, which expressed high levels of Ptp4a3. Tumor cells deficient for Ptp4a3 exhibited reduced clonogenicity and growth potential relative to WT cells as determined by limiting dilution analysis. Importantly, expanded tumor cells from WT mice readily formed secondary tumors when transplanted into nude mice, while tumor cells without Ptp4a3 expression failed to form secondary tumors and thus were not tumorigenic. These results demonstrate that Ptp4a3 contributes to the malignant phenotype of tumor-initiating cells and supports its role as a potential therapeutic target to inhibit tumor self-renewal and metastasis.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24950307      PMCID: PMC4090270          DOI: 10.1016/j.scr.2014.05.004

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  21 in total

1.  Culture of phenotypically defined hematopoietic stem cells and other progenitors at limiting dilution on Dexter monolayers.

Authors:  K Weilbaecher; I Weissman; K Blume; S Heimfeld
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

2.  A phosphatase associated with metastasis of colorectal cancer.

Authors:  S Saha; A Bardelli; P Buckhaults; V E Velculescu; C Rago; B St Croix; K E Romans; M A Choti; C Lengauer; K W Kinzler; B Vogelstein
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

3.  Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3β/β-catenin pathway.

Authors:  Yi Chen; Dongke Yu; Caixia Zhang; Boyang Shang; Hongwei He; Jinjing Chen; Hao Zhang; Wuli Zhao; Zhen Wang; Xiaoyu Xu; Yongsu Zhen; Rong-guang Shao
Journal:  Mol Carcinog       Date:  2013-07-16       Impact factor: 4.784

4.  Identification and isolation of candidate human colonic clonogenic cells based on cell surface integrin expression.

Authors:  Koji Fujimoto; R Daniel Beauchamp; Robert H Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 5.  Regulation of intestinal cancer stem cells.

Authors:  Neil Ashley
Journal:  Cancer Lett       Date:  2012-04-27       Impact factor: 8.679

6.  Identification and expansion of human colon-cancer-initiating cells.

Authors:  Lucia Ricci-Vitiani; Dario G Lombardi; Emanuela Pilozzi; Mauro Biffoni; Matilde Todaro; Cesare Peschle; Ruggero De Maria
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

7.  HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

Authors:  Hongbiao Huang; Ningning Liu; Changshan Yang; Siyan Liao; Haiping Guo; Kai Zhao; Xiaofen Li; Shouting Liu; Lixia Guan; Chunjiao Liu; Li Xu; Change Zhang; Wenbin Song; Bing Li; Ping Tang; Q Ping Dou; Jinbao Liu
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

8.  Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer.

Authors:  Mark W Zimmerman; Gregg E Homanics; John S Lazo
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

9.  Phosphatase of regenerating liver-3 directly interacts with integrin β1 and regulates its phosphorylation at tyrosine 783.

Authors:  Wei Tian; Like Qu; Lin Meng; Caiyun Liu; Jian Wu; Chengchao Shou
Journal:  BMC Biochem       Date:  2012-10-23       Impact factor: 4.059

10.  Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells.

Authors:  M Pignatelli; D Liu; M M Nasim; G W Stamp; S Hirano; M Takeichi
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

View more
  11 in total

Review 1.  Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.

Authors:  Lakshmi Reddy Bollu; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.

Authors:  Kelley E McQueeney; Joseph M Salamoun; Jennifer G Ahn; Paula Pekic; Isabella K Blanco; Heather L Struckman; Elizabeth R Sharlow; Peter Wipf; John S Lazo
Journal:  FASEB J       Date:  2018-05-10       Impact factor: 5.191

Review 3.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

4.  Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.

Authors:  Sheng-Yi Lin; Yue-Xun Lee; Sung-Liang Yu; Gee-Chen Chang; Jeremy J W Chen
Journal:  Oncotarget       Date:  2016-04-19

5.  PRL-3 promotes telomere deprotection and chromosomal instability.

Authors:  Shenyi Lian; Lin Meng; Yongyong Yang; Ting Ma; Xiaofang Xing; Qin Feng; Qian Song; Caiyun Liu; Zhihua Tian; Like Qu; Chengchao Shou
Journal:  Nucleic Acids Res       Date:  2017-06-20       Impact factor: 16.971

6.  A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.

Authors:  Jianbiao Zhou; Sabrina Hui-Min Toh; Zit-Liang Chan; Jessie Yiying Quah; Jing-Yuan Chooi; Tuan Zea Tan; Phyllis S Y Chong; Qi Zeng; Wee-Joo Chng
Journal:  J Hematol Oncol       Date:  2018-03-07       Impact factor: 17.388

7.  Chemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling.

Authors:  Balint Csoboz; Imre Gombos; Eniko Tatrai; Jozsef Tovari; Anna L Kiss; Ibolya Horvath; Laszlo Vigh
Journal:  Cell Commun Signal       Date:  2018-08-29       Impact factor: 5.712

8.  A retrospective cohort study of clinical value of PRL-3 in stage III human colorectal cancer.

Authors:  Chuanyuan Liu; Wu Zhong; Laiyang Xia; Chuanfa Fang; Hongquan Liu; Xiaochun Liu
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

9.  Comprehensive assembly of novel transcripts from unmapped human RNA-Seq data and their association with cancer.

Authors:  Majid Kazemian; Min Ren; Jian-Xin Lin; Wei Liao; Rosanne Spolski; Warren J Leonard
Journal:  Mol Syst Biol       Date:  2015-08-07       Impact factor: 11.429

10.  MUFFINN: cancer gene discovery via network analysis of somatic mutation data.

Authors:  Ara Cho; Jung Eun Shim; Eiru Kim; Fran Supek; Ben Lehner; Insuk Lee
Journal:  Genome Biol       Date:  2016-06-23       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.